China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN)

China Universal Asset Management Co. Ltd. purchased a new stake in shares of Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,396 shares of the company’s stock, valued at approximately $575,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BHVN. Squarepoint Ops LLC bought a new stake in Biohaven during the 2nd quarter worth about $592,000. AQR Capital Management LLC raised its stake in shares of Biohaven by 234.3% during the second quarter. AQR Capital Management LLC now owns 54,361 shares of the company’s stock worth $1,887,000 after buying an additional 38,101 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Biohaven by 12.3% in the second quarter. The Manufacturers Life Insurance Company now owns 183,772 shares of the company’s stock valued at $6,379,000 after buying an additional 20,154 shares during the period. Algert Global LLC boosted its stake in Biohaven by 5.9% in the second quarter. Algert Global LLC now owns 7,402 shares of the company’s stock valued at $257,000 after acquiring an additional 412 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in Biohaven by 20.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 20,700 shares of the company’s stock worth $1,034,000 after acquiring an additional 3,500 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs acquired 29,000 shares of Biohaven stock in a transaction dated Monday, December 30th. The stock was bought at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the purchase, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This represents a 1.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 16.00% of the stock is owned by insiders.

Biohaven Price Performance

BHVN stock opened at $38.30 on Monday. The business has a 50-day moving average of $39.65 and a 200-day moving average of $42.57. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The stock has a market capitalization of $3.87 billion, a P/E ratio of -4.10 and a beta of 1.29.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Equities analysts expect that Biohaven Ltd. will post -8.85 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BHVN. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price target (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. TD Cowen upped their price target on Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $59.00 price objective on shares of Biohaven in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Thirteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Biohaven presently has a consensus rating of “Buy” and an average target price of $63.00.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.